{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:19:09Z","timestamp":1773361149723,"version":"3.50.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To explore the mechanism of E2F transcription Factor 1 (E2F-1)-mediated ataxia-telangiectasia-mutated protein (ATM) in cisplatin (DDP)-resistant nasopharyngeal carcinoma (NPC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>E2F-1 and ATM expression was assessed in DDP-resistant NPC cell lines (CNE2\/DDP and HNE1\/DDP) and parental cells. Then, DDP-resistant NPC cells were transfected with control shRNA (short hairpin RNA) or E2F-1 shRNAs with or without ATM lentiviral activation particles. The half maximal inhibitory concentration (IC50) was evaluated by 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assay, and the cell cycle and cell proliferation were measured by flow cytometry and EdU staining, respectively. In addition, the expression of genes and proteins was quantified by quantitative reverse-transcription polymerase chain reaction (qRT\u2013PCR) and western blotting, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Both E2F-1 and ATM expression in DDP-resistant NPC cells was much higher than that in parental cells. E2F-1 shRNA reduced ATM expression in DDP-resistant NPC cells, but ATM overexpression had no significant effect on E2F-1. ATM overexpression enhanced DDP resistance in DDP-resistant NPC cells with increased IC50 values, which was reversed by E2F-1 inhibition. Meanwhile, ATM overexpression resulted in upregulation of ABCA2 and ABCA5 in DDP-resistant NPC cells, induced elevations in the transition of the cells into S-phase, and increased cell proliferation with enhanced expression of cyclin E1, CDK2, and Ki67, which was reversed by E2F-1 shRNAs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Downregulation of E2F-1, possibly by regulating ATM, could block the cell cycle in the G1 phase and reduce the proliferation of CNE2\/DDP cells, thereby reversing the resistance of human NPC cells to DDP.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12957-022-02546-w","type":"journal-article","created":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T16:14:31Z","timestamp":1647620071000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Positive regulation of ataxia-telangiectasia-mutated protein (ATM) by E2F transcription Factor 1 (E2F-1) in cisplatin-resistant nasopharyngeal carcinoma cells"],"prefix":"10.1186","volume":"20","author":[{"given":"Zun-Yan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Yuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Ze","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,18]]},"reference":[{"key":"2546_CR1","doi-asserted-by":"publisher","first-page":"629264","DOI":"10.3389\/fphar.2021.629264","volume":"12","author":"W Hao","year":"2021","unstructured":"Hao W, Wu L, Cao L, Yu J, Ning L, Wang J, et al. Radioresistant nasopharyngeal carcinoma cells exhibited decreased cisplatin sensitivity by inducing SLC1A6 expression. Front Pharmacol. 2021;12:629264.","journal-title":"Front Pharmacol"},{"key":"2546_CR2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12957-021-02461-6","volume":"20","author":"Z Yan","year":"2022","unstructured":"Yan Z, Lijuan Y, Yinhang W, Yin J, Jiamin X, Wei W, et al. Screening and analysis of RNAs associated with activated memory CD4 and CD8 T cells in liver cancer. World J Surg Oncol. 2022;20:2.","journal-title":"World J Surg Oncol"},{"key":"2546_CR3","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41392-020-00340-2","volume":"5","author":"Y Kang","year":"2020","unstructured":"Kang Y, He W, Ren C, Qiao J, Guo Q, Hu J, et al. Advances in targeted therapy mainly based on signal pathways for nasopharyngeal carcinoma. Signal Transduct Target Ther. 2020;5:245.","journal-title":"Signal Transduct Target Ther"},{"key":"2546_CR4","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s12957-021-02380-6","volume":"19","author":"M Zheng","year":"2021","unstructured":"Zheng M, Liu J, Meng C, Tang K, Liao J. Prognostic and clinicopathological importance of microRNA-140 expression in cancer patients: a meta-analysis. World J Surg Oncol. 2021;19:266.","journal-title":"World J Surg Oncol"},{"key":"2546_CR5","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12957-021-02354-8","volume":"19","author":"J Cai","year":"2021","unstructured":"Cai J, Zhou M, Xu J. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma. World J Surg Oncol. 2021;19:241.","journal-title":"World J Surg Oncol"},{"key":"2546_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12957-021-02479-w","volume":"20","author":"W Mu","year":"2022","unstructured":"Mu W, Xie Y, Li J, Yan R, Zhang J, Liu Y, et al. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma. World J Surg Oncol. 2022;20:22.","journal-title":"World J Surg Oncol"},{"key":"2546_CR7","doi-asserted-by":"publisher","first-page":"873","DOI":"10.6004\/jnccn.2020.0031","volume":"18","author":"DG Pfister","year":"2020","unstructured":"Pfister DG, Spencer S, Adelstein D, Adkins D, Anzai Y, Brizel DM, et al. Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18:873\u201398.","journal-title":"J Natl Compr Canc Netw"},{"key":"2546_CR8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.semradonc.2012.03.008","volume":"22","author":"AW Lee","year":"2012","unstructured":"Lee AW, Lin JC, Ng WT. Current management of nasopharyngeal cancer. Semin Radiat Oncol. 2012;22:233\u201344.","journal-title":"Semin Radiat Oncol"},{"issue":"4","key":"2546_CR9","first-page":"97","volume":"11","author":"A Brown","year":"2019","unstructured":"Brown A, Kumar S, Tchounwou PB. Cisplatin-based chemotherapy of human cancers. J Cancer Sci Ther. 2019;11(4):97.","journal-title":"J Cancer Sci Ther"},{"key":"2546_CR10","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1080\/15384047.2018.1472192","volume":"19","author":"K Wang","year":"2018","unstructured":"Wang K, Chen Z, Long L, Tao Y, Wu Q, Xiang M, et al. iTRAQ-based quantitative proteomic analysis of differentially expressed proteins in chemoresistant nasopharyngeal carcinoma. Cancer Biol Ther. 2018;19:809\u201324.","journal-title":"Cancer Biol Ther"},{"key":"2546_CR11","doi-asserted-by":"publisher","first-page":"e2874","DOI":"10.1038\/cddis.2017.271","volume":"8","author":"CM Kuang","year":"2017","unstructured":"Kuang CM, Fu X, Hua YJ, Shuai WD, Ye ZH, Li Y, et al. BST2 confers cisplatin resistance via NF-kappaB signaling in nasopharyngeal cancer. Cell Death Dis. 2017;8:e2874.","journal-title":"Cell Death Dis"},{"key":"2546_CR12","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12957-017-1127-2","volume":"15","author":"T Mou","year":"2017","unstructured":"Mou T, Zhu D, Wei X, Li T, Zheng D, Pu J, et al. Identification and interaction analysis of key genes and microRNAs in hepatocellular carcinoma by bioinformatics analysis. World J Surg Oncol. 2017;15:63.","journal-title":"World J Surg Oncol"},{"key":"2546_CR13","doi-asserted-by":"publisher","first-page":"6281635","DOI":"10.1155\/2020\/6281635","volume":"2020","author":"P Liao","year":"2020","unstructured":"Liao P, Han S, Qu H. Expression, prognosis, and immune infiltrates analyses of E2Fs in human brain and CNS cancer. Biomed Res Int. 2020;2020:6281635.","journal-title":"Biomed Res Int"},{"key":"2546_CR14","doi-asserted-by":"publisher","first-page":"963689720929308","DOI":"10.1177\/0963689720929308","volume":"29","author":"ZH Wu","year":"2020","unstructured":"Wu ZH, Yun T, Cheng Q. Data mining identifies six proteins that can act as prognostic markers for head and neck squamous cell carcinoma. Cell Transplant. 2020;29:963689720929308.","journal-title":"Cell Transplant"},{"key":"2546_CR15","doi-asserted-by":"publisher","first-page":"599332","DOI":"10.3389\/fmolb.2020.599332","volume":"7","author":"S Fouad","year":"2020","unstructured":"Fouad S, Hauton D, D\u2019Angiolella V. E2F1: cause and consequence of DNA replication stress. Front Mol Biosci. 2020;7:599332.","journal-title":"Front Mol Biosci"},{"key":"2546_CR16","doi-asserted-by":"publisher","first-page":"102858","DOI":"10.1016\/j.dnarep.2020.102858","volume":"90","author":"M El Dika","year":"2020","unstructured":"El Dika M. Redirecting E2F1 to TA-p73 improves cancer therapy through apoptotic induction. DNA Repair (Amst). 2020;90:102858.","journal-title":"DNA Repair (Amst)"},{"key":"2546_CR17","doi-asserted-by":"publisher","first-page":"188336","DOI":"10.1016\/j.bbcan.2019.188336","volume":"1873","author":"JN Chun","year":"2020","unstructured":"Chun JN, Cho M, Park S, So I, Jeon JH. The conflicting role of E2F1 in prostate cancer: a matter of cell context or interpretational flexibility? Biochim Biophys Acta Rev Cancer. 2020;1873:188336.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2546_CR18","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.bbrc.2020.01.158","volume":"524","author":"P Liu","year":"2020","unstructured":"Liu P, Zhang X, Li Z, Wei L, Peng Q, Liu C, et al. A significant role of transcription factors E2F in inflammation and tumorigenesis of nasopharyngeal carcinoma. Biochem Biophys Res Commun. 2020;524:816\u201324.","journal-title":"Biochem Biophys Res Commun"},{"key":"2546_CR19","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1007\/s13277-013-1345-3","volume":"35","author":"HP Hsu","year":"2014","unstructured":"Hsu HP, Li CF, Lee SW, Wu WR, Chen TJ, Chang KY, et al. Overexpression of stathmin 1 confers an independent prognostic indicator in nasopharyngeal carcinoma. Tumour Biol. 2014;35:2619\u201329.","journal-title":"Tumour Biol"},{"key":"2546_CR20","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.3892\/or.2017.5413","volume":"37","author":"Y Tan","year":"2017","unstructured":"Tan Y, Wei X, Zhang W, Wang X, Wang K, Du B, et al. Resveratrol enhances the radiosensitivity of nasopharyngeal carcinoma cells by downregulating E2F1. Oncol Rep. 2017;37:1833\u201341.","journal-title":"Oncol Rep"},{"issue":"5","key":"2546_CR21","doi-asserted-by":"publisher","first-page":"972","DOI":"10.3390\/cancers13050972","volume":"13","author":"GM Rather","year":"2021","unstructured":"Rather GM, Anyanwu M, Minko T, Garbuzenko O, Szekely Z, Bertino JR. Anti-tumor effects of a penetratin peptide targeting transcription of E2F-1, 2 and 3a is enhanced when used in combination with pemetrexed or cisplatin. Cancers (Basel). 2021;13(5):972.","journal-title":"Cancers (Basel)"},{"key":"2546_CR22","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3748\/wjg.v26.i5.499","volume":"26","author":"H Zheng","year":"2020","unstructured":"Zheng H, Wang JJ, Yang XR, Yu YL. Upregulation of miR-34c after silencing E2F transcription factor 1 inhibits paclitaxel combined with cisplatin resistance in gastric cancer cells. World J Gastroenterol. 2020;26:499\u2013513.","journal-title":"World J Gastroenterol"},{"key":"2546_CR23","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.taap.2016.10.022","volume":"313","author":"M Yan","year":"2016","unstructured":"Yan M, Tang C, Ma Z, Huang S, Dong Z. DNA damage response in nephrotoxic and ischemic kidney injury. Toxicol Appl Pharmacol. 2016;313:104\u20138.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"Suppl 1","key":"2546_CR24","doi-asserted-by":"publisher","first-page":"E384","DOI":"10.1002\/hed.24004","volume":"38","author":"JJ Ko","year":"2016","unstructured":"Ko JJ, Klimowicz AC, Jagdis A, Phan T, Laskin J, Lau HY, et al. ATM, THMS, and RRM1 protein expression in nasopharyngeal carcinomas treated with curative intent. Head Neck. 2016;38(Suppl 1):E384\u201391.","journal-title":"Head Neck"},{"key":"2546_CR25","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13046-019-1161-8","volume":"38","author":"M Shen","year":"2019","unstructured":"Shen M, Xu Z, Xu W, Jiang K, Zhang F, Ding Q, et al. Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK\/STAT3\/PD-L1 pathway. J Exp Clin Cancer Res. 2019;38:149.","journal-title":"J Exp Clin Cancer Res"},{"issue":"12","key":"2546_CR26","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.3390\/cancers11121913","volume":"11","author":"M Takeuchi","year":"2019","unstructured":"Takeuchi M, Tanikawa M, Nagasaka K, Oda K, Kawata Y, Oki S, et al. Anti-tumor effect of inhibition of DNA damage response proteins, ATM and ATR, in endometrial cancer cells. Cancers (Basel). 2019;11(12):1913.","journal-title":"Cancers (Basel)"},{"key":"2546_CR27","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/sj.onc.1206144","volume":"22","author":"E Berkovich","year":"2003","unstructured":"Berkovich E, Ginsberg D. ATM is a target for positive regulation by E2F-1. Oncogene. 2003;22:161\u20137.","journal-title":"Oncogene"},{"key":"2546_CR28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13046-018-0724-4","volume":"37","author":"ZW Chang","year":"2018","unstructured":"Chang ZW, Jia YX, Zhang WJ, Song LJ, Gao M, Li MJ, et al. LncRNA-TUSC7\/miR-224 affected chemotherapy resistance of esophageal squamous cell carcinoma by competitively regulating DESC1. J Exp Clin Cancer Res. 2018;37:56.","journal-title":"J Exp Clin Cancer Res"},{"key":"2546_CR29","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1158\/0008-5472.CAN-08-3131","volume":"69","author":"N Gaspar","year":"2009","unstructured":"Gaspar N, Sharp SY, Pacey S, Jones C, Walton M, Vassal G, et al. Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. Cancer Res. 2009;69:1966\u201375.","journal-title":"Cancer Res"},{"key":"2546_CR30","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.molmed.2012.10.009","volume":"19","author":"BM Putzer","year":"2013","unstructured":"Putzer BM, Engelmann D. E2F1 apoptosis counterattacked: evil strikes back. Trends Mol Med. 2013;19:89\u201398.","journal-title":"Trends Mol Med"},{"key":"2546_CR31","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.4161\/cc.21476","volume":"11","author":"V Alla","year":"2012","unstructured":"Alla V, Kowtharapu BS, Engelmann D, Emmrich S, Schmitz U, Steder M, et al. E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73\/DNp73-miR-205 circuitry. Cell Cycle. 2012;11:3067\u201378.","journal-title":"Cell Cycle"},{"key":"2546_CR32","doi-asserted-by":"publisher","first-page":"682","DOI":"10.3892\/mmr.2014.2662","volume":"11","author":"Z Dong","year":"2015","unstructured":"Dong Z, Ren L, Lin L, Li J, Huang Y, Li J. Effect of microRNA-21 on multidrug resistance reversal in A549\/DDP human lung cancer cells. Mol Med Rep. 2015;11:682\u201390.","journal-title":"Mol Med Rep"},{"key":"2546_CR33","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0003-9861(03)00054-7","volume":"412","author":"C Stevens","year":"2003","unstructured":"Stevens C, La Thangue NB. E2F and cell cycle control: a double-edged sword. Arch Biochem Biophys. 2003;412:157\u201369.","journal-title":"Arch Biochem Biophys"},{"key":"2546_CR34","doi-asserted-by":"publisher","first-page":"7809","DOI":"10.1158\/0008-5472.CAN-05-0888","volume":"65","author":"A Wang","year":"2005","unstructured":"Wang A, Li CJ, Reddy PV, Pardee AB. Cancer chemotherapy by deoxynucleotide depletion and E2F-1 elevation. Cancer Res. 2005;65:7809\u201314.","journal-title":"Cancer Res"},{"key":"2546_CR35","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/365349a0","volume":"365","author":"DG Johnson","year":"1993","unstructured":"Johnson DG, Schwarz JK, Cress WD, Nevins JR. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature. 1993;365:349\u201352.","journal-title":"Nature"},{"key":"2546_CR36","first-page":"171","volume":"36","author":"C Lian","year":"2014","unstructured":"Lian C, Yang J, Wang X, Xie Y, Xiao Q. Reversion of multidrug resistance of human gastric cancer SGC7901\/DDP cells by E2F-1 gene silencing. Zhonghua Zhong Liu Za Zhi. 2014;36:171\u20136.","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"2546_CR37","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/jcb.24652","volume":"115","author":"LH Yan","year":"2014","unstructured":"Yan LH, Wang XT, Yang J, Kong FB, Lian C, Wei WY, et al. Reversal of multidrug resistance in gastric cancer cells by E2F-1 downregulation in vitro and in vivo. J Cell Biochem. 2014;115:34\u201341.","journal-title":"J Cell Biochem"},{"key":"2546_CR38","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1046\/j.1523-1755.1999.00705.x","volume":"56","author":"S Inoshita","year":"1999","unstructured":"Inoshita S, Terada Y, Nakashima O, Kuwahara M, Sasaki S, Marumo F. Regulation of the G1\/S transition phase in mesangial cells by E2F1. Kidney Int. 1999;56:1238\u201341.","journal-title":"Kidney Int"},{"key":"2546_CR39","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1186\/s12935-020-01597-x","volume":"20","author":"Y Huang","year":"2020","unstructured":"Huang Y, Wu H, Li X. Novel sequential treatment with palbociclib enhances the effect of cisplatin in RB-proficient triple-negative breast cancer. Cancer Cell Int. 2020;20:501.","journal-title":"Cancer Cell Int"},{"key":"2546_CR40","first-page":"1863","volume":"40","author":"Y Gu","year":"2018","unstructured":"Gu Y, Wang X, Liu H, Li G, Yu W, Ma Q. SET7\/9 promotes hepatocellular carcinoma progression through regulation of E2F1. Oncol Rep. 2018;40:1863\u201374.","journal-title":"Oncol Rep"},{"key":"2546_CR41","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1111\/cas.13793","volume":"109","author":"MM Chang","year":"2018","unstructured":"Chang MM, Lai MS, Hong SY, Pan BS, Huang H, Yang SH, et al. FGF9\/FGFR2 increase cell proliferation by activating ERK1\/2, Rb\/E2F1, and cell cycle pathways in mouse Leydig tumor cells. Cancer Sci. 2018;109:3503\u201318.","journal-title":"Cancer Sci"},{"key":"2546_CR42","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1186\/s12957-021-02449-2","volume":"19","author":"G Xu","year":"2021","unstructured":"Xu G, Meng Y, Wang L, Dong B, Peng F, Liu S, et al. miRNA-214-5p inhibits prostate cancer cell proliferation by targeting SOX4. World J Surg Oncol. 2021;19:338.","journal-title":"World J Surg Oncol"},{"key":"2546_CR43","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12957-021-02202-9","volume":"19","author":"H Yang","year":"2021","unstructured":"Yang H, Huo J, Li X. Identification and validation of a five-gene prognostic signature for hepatocellular carcinoma. World J Surg Oncol. 2021;19:90.","journal-title":"World J Surg Oncol"},{"key":"2546_CR44","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1038\/sj.onc.1204242","volume":"20","author":"B Eymin","year":"2001","unstructured":"Eymin B, Gazzeri S, Brambilla C, Brambilla E. Distinct pattern of E2F1 expression in human lung tumours: E2F1 is upregulated in small cell lung carcinoma. Oncogene. 2001;20:1678\u201387.","journal-title":"Oncogene"},{"key":"2546_CR45","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1053\/hupa.2001.24325","volume":"32","author":"M Orjuela","year":"2001","unstructured":"Orjuela M, Orlow I, Dudas M, Ponce-Castaneda MV, Ridaura C, Leal C, et al. Alterations of cell cycle regulators affecting the RB pathway in nonfamilial retinoblastoma. Hum Pathol. 2001;32:537\u201344.","journal-title":"Hum Pathol"},{"key":"2546_CR46","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s12094-017-1774-3","volume":"20","author":"C Yang","year":"2018","unstructured":"Yang C, Zhang J, Ding M, Xu K, Li L, Mao L, et al. Ki67 targeted strategies for cancer therapy. Clin Transl Oncol. 2018;20:570\u20135.","journal-title":"Clin Transl Oncol"},{"key":"2546_CR47","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1038\/sj.onc.1203444","volume":"19","author":"TK Pandita","year":"2000","unstructured":"Pandita TK, Lieberman HB, Lim DS, Dhar S, Zheng W, Taya Y, et al. Ionizing radiation activates the ATM kinase throughout the cell cycle. Oncogene. 2000;19:1386\u201391.","journal-title":"Oncogene"},{"key":"2546_CR48","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1089\/cbr.2019.2787","volume":"34","author":"W Yan","year":"2019","unstructured":"Yan W, Yang Y, Yang W. Inhibition of SKP2 activity impaired ATM-mediated DNA repair and enhanced sensitivity of cisplatin-resistant mantle cell lymphoma cells. Cancer Biother Radiopharm. 2019;34:451\u20138.","journal-title":"Cancer Biother Radiopharm"},{"key":"2546_CR49","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1080\/15384047.2017.1345391","volume":"18","author":"F Zhang","year":"2017","unstructured":"Zhang F, Shen M, Yang L, Yang X, Tsai Y, Keng PC, et al. Simultaneous targeting of ATM and Mcl-1 increases cisplatin sensitivity of cisplatin-resistant non-small cell lung cancer. Cancer Biol Ther. 2017;18:606\u201315.","journal-title":"Cancer Biol Ther"},{"key":"2546_CR50","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.yexcr.2018.03.006","volume":"366","author":"K Li","year":"2018","unstructured":"Li K, Yan H, Guo W, Tang M, Zhao X, Tong A, et al. ATM inhibition induces synthetic lethality and enhances sensitivity of PTEN-deficient breast cancer cells to cisplatin. Exp Cell Res. 2018;366:24\u201333.","journal-title":"Exp Cell Res"},{"key":"2546_CR51","doi-asserted-by":"publisher","first-page":"208","DOI":"10.5483\/BMBRep.2019.52.3.249","volume":"52","author":"D Li","year":"2019","unstructured":"Li D, Ye L, Lei Y, Wan J, Chen H. Downregulation of FoxM1 sensitizes nasopharyngeal carcinoma cells to cisplatin via inhibition of MRN-ATM-mediated DNA repair. BMB Rep. 2019;52:208\u201313.","journal-title":"BMB Rep"},{"key":"2546_CR52","doi-asserted-by":"publisher","first-page":"e0178221","DOI":"10.1371\/journal.pone.0178221","volume":"12","author":"T Iwata","year":"2017","unstructured":"Iwata T, Uchino T, Koyama A, Johmura Y, Koyama K, Saito T, et al. The G2 checkpoint inhibitor CBP-93872 increases the sensitivity of colorectal and pancreatic cancer cells to chemotherapy. PLoS One. 2017;12:e0178221.","journal-title":"PLoS One"},{"key":"2546_CR53","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.pharmthera.2014.12.001","volume":"149","author":"AM Weber","year":"2015","unstructured":"Weber AM, Ryan AJ. ATM and ATR as therapeutic targets in cancer. Pharmacol Ther. 2015;149:124\u201338.","journal-title":"Pharmacol Ther"},{"key":"2546_CR54","doi-asserted-by":"publisher","first-page":"5700","DOI":"10.1074\/jbc.RA118.005699","volume":"294","author":"WP Folk","year":"2019","unstructured":"Folk WP, Kumari A, Iwasaki T, Pyndiah S, Johnson JC, Cassimere EK, et al. Loss of the tumor suppressor BIN1 enables ATM Ser\/Thr kinase activation by the nuclear protein E2F1 and renders cancer cells resistant to cisplatin. J Biol Chem. 2019;294:5700\u201319.","journal-title":"J Biol Chem"},{"key":"2546_CR55","doi-asserted-by":"publisher","first-page":"786","DOI":"10.18632\/oncotarget.6381","volume":"7","author":"A Cataldo","year":"2016","unstructured":"Cataldo A, Cheung DG, Balsari A, Tagliabue E, Coppola V, Iorio MV, et al. miR-302b enhances breast cancer cell sensitivity to cisplatin by regulating E2F1 and the cellular DNA damage response. Oncotarget. 2016;7:786\u201397.","journal-title":"Oncotarget"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-022-02546-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-022-02546-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-022-02546-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T23:07:52Z","timestamp":1666566472000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-022-02546-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,18]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2546"],"URL":"https:\/\/doi.org\/10.1186\/s12957-022-02546-w","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,18]]},"assertion":[{"value":"5 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required for this study in accordance with local\/ national guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent from participants was not required in accordance with local\/national guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}